Pirh2

References

• Beitel LK, Elhaji YA, Lumbroso R, Wing SS, Panet-Raymond V, Gottlieb B, Pinsky L, Trifiro MA. Cloning and characterization of an androgen receptor N-terminal-interacting protein with ubiquitin-protein ligase activity. J Mol Endocrinol 2002; 29:41 - 60; http://dx.doi.org/10.1677/jme.0.0290041; PMID: 12200228
   PubMed Web of Science ®Google Scholar
• Leng RP, Lin Y, Ma W, Wu H, Lemmers B, Chung S, Parant JM, Lozano G, Hakem R, Benchimol S. Pirh2, a p53-induced ubiquitin-protein ligase, promotes p53 degradation. Cell 2003; 112:779 - 91; http://dx.doi.org/10.1016/S0092-8674(03)00193-4; PMID: 12654245
   PubMed Web of Science ®Google Scholar
• Jung YS, Qian Y, Chen X. Pirh2 RING-finger E3 ubiquitin ligase: its role in tumorigenesis and cancer therapy. FEBS Lett 2012; 586:1397 - 402; http://dx.doi.org/10.1016/j.febslet.2012.03.052; PMID: 22673504
   PubMed Web of Science ®Google Scholar
• Jung YS, Qian Y, Yan W, Chen X. Pirh2 E3 ubiquitin ligase modulates keratinocyte differentiation through p63. J Invest Dermatol 2013; 133:1178 - 87; http://dx.doi.org/10.1038/jid.2012.466; PMID: 23235527
   PubMed Web of Science ®Google Scholar
• Yan W, Chen X, Zhang Y, Zhang J, Jung YS, Chen X. Arsenic suppresses cell survival via Pirh2-mediated proteasomal degradation of ΔNp63 protein. J Biol Chem 2013; 288:2907 - 13; http://dx.doi.org/10.1074/jbc.M112.428607; PMID: 23271742
   PubMed Web of Science ®Google Scholar
• Hakem A, Bohgaki M, Lemmers B, Tai E, Salmena L, Matysiak-Zablocki E, Jung YS, Karaskova J, Kaustov L, Duan S, et al. Role of Pirh2 in mediating the regulation of p53 and c-Myc. PLoS Genet 2011; 7:e1002360; http://dx.doi.org/10.1371/journal.pgen.1002360; PMID: 22125490
   PubMedGoogle Scholar
• Bohgaki M, Hakem A, Halaby MJ, Bohgaki T, Li Q, Bissey PA, Shloush J, Kislinger T, Sanchez O, Sheng Y, et al. The E3 ligase PIRH2 polyubiquitylates CHK2 and regulates its turnover. Cell Death Differ 2013; 20:812 - 22; http://dx.doi.org/10.1038/cdd.2013.7; PMID: 23449389
   PubMed Web of Science ®Google Scholar
• Zilfou JT, Lowe SW. Tumor suppressive functions of p53. Cold Spring Harb Perspect Biol 2009; 1:a001883; http://dx.doi.org/10.1101/cshperspect.a001883; PMID: 20066118
   PubMed Web of Science ®Google Scholar
• Bell HS, Ryan KM. Targeting the p53 family for cancer therapy: ‘big brother’ joins the fight. Cell Cycle 2007; 6:1995 - 2000; http://dx.doi.org/10.4161/cc.6.16.4614; PMID: 17721076
   PubMed Web of Science ®Google Scholar
• Marchenko ND, Wolff S, Erster S, Becker K, Moll UM. Monoubiquitylation promotes mitochondrial p53 translocation. EMBO J 2007; 26:923 - 34; http://dx.doi.org/10.1038/sj.emboj.7601560; PMID: 17268548
   PubMed Web of Science ®Google Scholar
• Brooks CL, Gu W. p53 regulation by ubiquitin. FEBS Lett 2011; 585:2803 - 9; http://dx.doi.org/10.1016/j.febslet.2011.05.022; PMID: 21624367
   PubMed Web of Science ®Google Scholar
• Sheng Y, Laister RC, Lemak A, Wu B, Tai E, Duan S, Lukin J, Sunnerhagen M, Srisailam S, Karra M, et al. Molecular basis of Pirh2-mediated p53 ubiquitylation. Nat Struct Mol Biol 2008; 15:1334 - 42; http://dx.doi.org/10.1038/nsmb.1521; PMID: 19043414
   PubMed Web of Science ®Google Scholar
• Levrero M, De Laurenzi V, Costanzo A, Gong J, Wang JY, Melino G. The p53/p63/p73 family of transcription factors: overlapping and distinct functions. J Cell Sci 2000; 113:1661 - 70; PMID: 10769197
   PubMed Web of Science ®Google Scholar
• Amelio I, Grespi F, Annicchiarico-Petruzzelli M, Melino G. p63 the guardian of human reproduction. Cell Cycle 2012; 11:4545 - 51; http://dx.doi.org/10.4161/cc.22819; PMID: 23165243
   PubMed Web of Science ®Google Scholar
• Zawacka-Pankau J, Kostecka A, Sznarkowska A, Hedström E, Kawiak A. p73 tumor suppressor protein: a close relative of p53 not only in structure but also in anti-cancer approach?. Cell Cycle 2010; 9:720 - 8; http://dx.doi.org/10.4161/cc.9.4.10668; PMID: 20160513
   PubMed Web of Science ®Google Scholar
• Allocati N, Di Ilio C, De Laurenzi V. p63/p73 in the control of cell cycle and cell death. Exp Cell Res 2012; 318:1285 - 90; http://dx.doi.org/10.1016/j.yexcr.2012.01.023; PMID: 22326462
   PubMed Web of Science ®Google Scholar
• McKeon F, Melino G. Fog of war: the emerging p53 family. Cell Cycle 2007; 6:229 - 32; http://dx.doi.org/10.4161/cc.6.3.3876; PMID: 17297295
   PubMed Web of Science ®Google Scholar
• Yang A, Walker N, Bronson R, Kaghad M, Oosterwegel M, Bonnin J, Vagner C, Bonnet H, Dikkes P, Sharpe A, et al. p73-deficient mice have neurological, pheromonal and inflammatory defects but lack spontaneous tumours. Nature 2000; 404:99 - 103; http://dx.doi.org/10.1038/35003607; PMID: 10716451
   PubMed Web of Science ®Google Scholar
• Flores ER, Sengupta S, Miller JB, Newman JJ, Bronson R, Crowley D, Yang A, McKeon F, Jacks T. Tumor predisposition in mice mutant for p63 and p73: evidence for broader tumor suppressor functions for the p53 family. Cancer Cell 2005; 7:363 - 73; http://dx.doi.org/10.1016/j.ccr.2005.02.019; PMID: 15837625
   PubMed Web of Science ®Google Scholar
• Garcia V, Silva J, Dominguez G, García JM, Peña C, Rodriguez R, Provencio M, España P, Bonilla F. Overexpression of p16INK4a correlates with high expression of p73 in breast carcinomas. Mutat Res 2004; 554:215 - 21; http://dx.doi.org/10.1016/j.mrfmmm.2004.04.008; PMID: 15450420
   PubMed Web of Science ®Google Scholar
• Tomasini R, Mak TW, Melino G. The impact of p53 and p73 on aneuploidy and cancer. Trends Cell Biol 2008; 18:244 - 52; http://dx.doi.org/10.1016/j.tcb.2008.03.003; PMID: 18406616
   PubMed Web of Science ®Google Scholar
• Lee H, Kimelman D. A dominant-negative form of p63 is required for epidermal proliferation in zebrafish. Dev Cell 2002; 2:607 - 16; http://dx.doi.org/10.1016/S1534-5807(02)00166-1; PMID: 12015968
   PubMed Web of Science ®Google Scholar
• Peschiaroli A, Scialpi F, Bernassola F, Pagano M, Melino G. The F-box protein FBXO45 promotes the proteasome-dependent degradation of p73. Oncogene 2009; 28:3157 - 66; http://dx.doi.org/10.1038/onc.2009.177; PMID: 19581926
   PubMed Web of Science ®Google Scholar
• Rossi M, De Laurenzi V, Munarriz E, Green DR, Liu YC, Vousden KH, Cesareni G, Melino G. The ubiquitin-protein ligase Itch regulates p73 stability. EMBO J 2005; 24:836 - 48; http://dx.doi.org/10.1038/sj.emboj.7600444; PMID: 15678106
   PubMed Web of Science ®Google Scholar
• Jung YS, Qian Y, Chen X. The p73 tumor suppressor is targeted by Pirh2 RING finger E3 ubiquitin ligase for the proteasome-dependent degradation. J Biol Chem 2011; 286:35388 - 95; http://dx.doi.org/10.1074/jbc.M111.261537; PMID: 21852228
   PubMed Web of Science ®Google Scholar
• Wu H, Zeinab RA, Flores ER, Leng RP. Pirh2, a ubiquitin E3 ligase, inhibits p73 transcriptional activity by promoting its ubiquitination. Mol Cancer Res 2011; 9:1780 - 90; http://dx.doi.org/10.1158/1541-7786.MCR-11-0157; PMID: 21994467
   PubMed Web of Science ®Google Scholar
• Chu IM, Hengst L, Slingerland JM. The Cdk inhibitor p27 in human cancer: prognostic potential and relevance to anticancer therapy. Nat Rev Cancer 2008; 8:253 - 67; http://dx.doi.org/10.1038/nrc2347; PMID: 18354415
   PubMed Web of Science ®Google Scholar
• Lu Z, Hunter T. Ubiquitylation and proteasomal degradation of the p21(Cip1), p27(Kip1) and p57(Kip2) CDK inhibitors. Cell Cycle 2010; 9:2342 - 52; http://dx.doi.org/10.4161/cc.9.12.11988; PMID: 20519948
   PubMed Web of Science ®Google Scholar
• Hattori T, Isobe T, Abe K, Kikuchi H, Kitagawa K, Oda T, Uchida C, Kitagawa M. Pirh2 promotes ubiquitin-dependent degradation of the cyclin-dependent kinase inhibitor p27Kip1. Cancer Res 2007; 67:10789 - 95; http://dx.doi.org/10.1158/0008-5472.CAN-07-2033; PMID: 18006823
   PubMed Web of Science ®Google Scholar
• Duan W, Gao L, Druhan LJ, Zhu WG, Morrison C, Otterson GA, Villalona-Calero MA. Expression of Pirh2, a newly identified ubiquitin protein ligase, in lung cancer. J Natl Cancer Inst 2004; 96:1718 - 21; http://dx.doi.org/10.1093/jnci/djh292; PMID: 15547185
   PubMed Web of Science ®Google Scholar
• Logan IR, Gaughan L, McCracken SR, Sapountzi V, Leung HY, Robson CN. Human PIRH2 enhances androgen receptor signaling through inhibition of histone deacetylase 1 and is overexpressed in prostate cancer. Mol Cell Biol 2006; 26:6502 - 10; http://dx.doi.org/10.1128/MCB.00147-06; PMID: 16914734
   PubMed Web of Science ®Google Scholar
• Jung YS, Hakem A, Hakem R, Chen X. Pirh2 E3 ubiquitin ligase monoubiquitinates DNA polymerase eta to suppress translesion DNA synthesis. Mol Cell Biol 2011; 31:3997 - 4006; http://dx.doi.org/10.1128/MCB.05808-11; PMID: 21791603
   PubMed Web of Science ®Google Scholar
• Antoni L, Sodha N, Collins I, Garrett MD. CHK2 kinase: cancer susceptibility and cancer therapy - two sides of the same coin?. Nat Rev Cancer 2007; 7:925 - 36; http://dx.doi.org/10.1038/nrc2251; PMID: 18004398
   PubMed Web of Science ®Google Scholar
• Lee SB, Kim SH, Bell DW, Wahrer DC, Schiripo TA, Jorczak MM, Sgroi DC, Garber JE, Li FP, Nichols KE, et al. Destabilization of CHK2 by a missense mutation associated with Li-Fraumeni Syndrome. Cancer Res 2001; 61:8062 - 7; PMID: 11719428
   PubMed Web of Science ®Google Scholar
• Matsuoka S, Huang M, Elledge SJ. Linkage of ATM to cell cycle regulation by the Chk2 protein kinase. Science 1998; 282:1893 - 7; http://dx.doi.org/10.1126/science.282.5395.1893; PMID: 9836640
   PubMed Web of Science ®Google Scholar
• Lavin MF. Ataxia-telangiectasia: from a rare disorder to a paradigm for cell signalling and cancer. Nat Rev Mol Cell Biol 2008; 9:759 - 69; http://dx.doi.org/10.1038/nrm2514; PMID: 18813293
   PubMed Web of Science ®Google Scholar
• Kass EM, Ahn J, Tanaka T, Freed-Pastor WA, Keezer S, Prives C. Stability of checkpoint kinase 2 is regulated via phosphorylation at serine 456. J Biol Chem 2007; 282:30311 - 21; http://dx.doi.org/10.1074/jbc.M704642200; PMID: 17715138
   PubMed Web of Science ®Google Scholar
• Kass EM, Poyurovsky MV, Zhu Y, Prives C. Mdm2 and PCAF increase Chk2 ubiquitination and degradation independently of their intrinsic E3 ligase activities. Cell Cycle 2009; 8:430 - 7; http://dx.doi.org/10.4161/cc.8.3.7624; PMID: 19176998
   PubMed Web of Science ®Google Scholar
• Lovly CM, Yan L, Ryan CE, Takada S, Piwnica-Worms H. Regulation of Chk2 ubiquitination and signaling through autophosphorylation of serine 379. Mol Cell Biol 2008; 28:5874 - 85; http://dx.doi.org/10.1128/MCB.00821-08; PMID: 18644861
   PubMed Web of Science ®Google Scholar
• Zhang D, Zaugg K, Mak TW, Elledge SJ. A role for the deubiquitinating enzyme USP28 in control of the DNA-damage response. Cell 2006; 126:529 - 42; http://dx.doi.org/10.1016/j.cell.2006.06.039; PMID: 16901786
   PubMed Web of Science ®Google Scholar